Directions for improvement of substitute heart valves: National Heart, Lung, and Blood Institute's working group report on heart valves

L. Henry Edmunds, Paul Didisheim(National Institutes of Health), Thomas H. Callahan(United States Food and Drug Administration), David M. Makanani, James M. Anderson(University of North Carolina at Chapel Hill), Larry V. McIntire(Freeman Health System), Edward A. Geiser(University of Florida), Frederick J. Schoen(Brigham and Women's Hospital), James H. Chesebro(Memorial Hermann), William Q. Meeker(Iowa State University), Gail K. Naughton(RegeneMed (United States)), Julio A. Panza(MedStar Washington Hospital Center), Sonja M. McKinlay(New England Research Institutes)
Journal of Biomedical Materials Research
January 1, 1997
10.1002/(sici)1097-4636(199723)38:3<263::aid-jbm11>3.3.co;2-p
Cited by 3

Related Papers

Spironolactone for Heart Failure with Preserved Ejection Fraction
|New England Journal of Medicine|2014|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Flow Effects on Prostacyclin Production by Cultured Human Endothelial Cells
|Science|1985|1.2k
Guidelines for the Management of Patients With Valvular Heart Disease
|Circulation|1998|1k